Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §102 only | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HILL, KEVIN KAI | 1 | 36.2% | +33.4% |
| TIWARI, VYOMA SHUBHAM | 1 | 30.2% | +46.7% |
| WEN, SHARON X | 1 | 56.5% | +32.8% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 63.8% | +59.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17310459 | TREATMENT INVOLVING CAR-ENGINEERED T CELLS AND CYTOKINES | WEN, SHARON X | 36d overdue |
| 17906448 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES | HILL, KEVIN KAI | 9d overdue |
| 17310463 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED CELLS FOR THE TREATMENT OF CLDN6-EXPRESSING CANCERS | CUNNINGCHEN, KATHLEEN MARY | 7d |
| 17781479 | IN VITRO AND IN VIVO GENE DELIVERY TO IMMUNE EFFECTOR CELLS USING NANOPARTICLES FUNCTIONALIZED WITH DESIGNED ANKYRIN REPEAT PROTEINS (DARPINS) | TIWARI, VYOMA SHUBHAM | 54d |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1634 | 1 |
| 1641 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17906448 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES | HILL, KEVIN KAI | 1638 | §102 | Non-Final OA | 9d overdue | Pending | Sep 15, 2022 |
| 17781479 | IN VITRO AND IN VIVO GENE DELIVERY TO IMMUNE EFFECTOR CELLS USING NANOPARTICLES FUNCTIONALIZED WITH DESIGNED ANKYRIN REPEAT PROTEINS (DARPINS) | TIWARI, VYOMA SHUBHAM | 1634 | §103 | Final Rejection | 54d | Pending | Jun 01, 2022 |
| 17310459 | TREATMENT INVOLVING CAR-ENGINEERED T CELLS AND CYTOKINES | WEN, SHARON X | 1641 | Other | Final Rejection | 36d overdue | Pending | Aug 04, 2021 |
| 17310463 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED CELLS FOR THE TREATMENT OF CLDN6-EXPRESSING CANCERS | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103 | Non-Final OA | 7d | Pending | Aug 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial